WEKO3
アイテム
{"_buckets": {"deposit": "704e98d3-ae60-44a4-9c08-94e840f5e150"}, "_deposit": {"id": "53889", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "53889"}, "status": "published"}, "_oai": {"id": "oai:tsukuba.repo.nii.ac.jp:00053889", "sets": ["2189", "6648", "1285", "1778", "7804"]}, "item_5_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-10", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageStart": "69", "bibliographicVolumeNumber": "102", "bibliographic_titles": [{}, {"bibliographic_title": "Journal of the Belgian Society of Radiology", "bibliographic_titleLang": "en"}]}]}, "item_5_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: Sorafenib has been used in the treatment of advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). Sorafenib-associated organ reduction have been reported on imaging, such as thyroid, pancreas and muscle, but there has been no research on prostate volume reduction (PVR).\n\nMethods: We retrospectively analyzed 26 patients (twenty with HCC and six patients with RCC) who underwent sorafenib therapy for 31 to 1225 days (median, 100 days). PVR was estimated by two independent readers using CT volumetry.\n\nResults: The sum of all prostate volumes measured by reader 1 was 24.2 ± 13.8 cm3 on the baseline CT and 20.4 ± 10.6 cm3 on the follow-up CT (p \u003c 0.001), and that measured by reader 2 was 22.3 ± 13.9 cm3 on the baseline CT and 19.2 ± 10.6 cm3 on the follow-up CT (p \u003c 0.001). The concordance correlation coefficient for the prostate volume measured by the two readers was 0.95 on the baseline CT scans and 0.94 on the follow-up CT scans. Sorafenib-associated PVR demonstrated slight dependence to the exposure time (r = –0.23). One patient with benign prostatic hyperplasia (BPH) showed PVR (from 80.4 to 61.5 cm3 [reader 1]; 83.4 to 61.6 cm3 [reader 2]) after sorafenib administration. Sorafenib-associated PVR occurred in patients both with and without underlying liver dysfunction with relative prostate volume changes of 86.7 ± 12.0% and 85.0 ± 9.0%, respectively.\n\nConclusion: Our study demonstrated significant PVR with sorafenib treatment in patients regardless of the presence of BPH and underlying liver dysfunction.", "subitem_description_type": "Abstract"}]}, "item_5_publisher_27": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Ubiquity Press"}]}, "item_5_relation_10": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "30386849", "subitem_relation_type_select": "PMID"}}]}, "item_5_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.5334/jbsr.1607", "subitem_relation_type_select": "DOI"}}]}, "item_5_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2018 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/."}]}, "item_5_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_5_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2514-8281", "subitem_source_identifier_type": "ISSN"}]}, "item_5_subject_20": {"attribute_name": "NIIサブジェクト", "attribute_value_mlt": [{"subitem_subject": "医学", "subitem_subject_scheme": "Other"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "森, 健作"}, {"creatorName": "モリ, ケンサク", "creatorNameLang": "ja-Kana"}, {"creatorName": "MORI, Kensaku", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "204941", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "80361343", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000080361343"}, {"nameIdentifier": "0000001917", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000001917"}]}, {"creatorNames": [{"creatorName": "小島, 崇宏"}, {"creatorName": "コジマ, タカヒロ", "creatorNameLang": "ja-Kana"}, {"creatorName": "KOJIMA, Takahiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "204280", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "40626892", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000040626892"}, {"nameIdentifier": "0000003161", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000003161"}]}, {"creatorNames": [{"creatorName": "福田, 邦明"}, {"creatorName": "フクダ, クニアキ", "creatorNameLang": "ja-Kana"}, {"creatorName": "FUKUDA, Kuniaki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "204750", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50447257", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000050447257"}, {"nameIdentifier": "0000001912", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000001912"}]}, {"creatorNames": [{"creatorName": "高橋, 一広"}, {"creatorName": "タカハシ, カズヒロ", "creatorNameLang": "ja-Kana"}, {"creatorName": "TAKAHASHI, Kazuhiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "204474", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "80794528", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000080794528"}, {"nameIdentifier": "0000004021", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000004021"}]}, {"creatorNames": [{"creatorName": "Takahashi, Hiroaki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "216976", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masuoka, Sota", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "216977", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nasu, Katsuhiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "216978", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishiguro, Toshitaka", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "216979", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hosokawa, Takahiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "216980", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Minami, Manabu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "216981", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-01-16"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "JBSR_102-1.pdf", "filesize": [{"value": "3.8 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_6", "mimetype": "application/pdf", "size": 3800000.0, "url": {"label": "JBSR_102-1", "url": "https://tsukuba.repo.nii.ac.jp/record/53889/files/JBSR_102-1.pdf"}, "version_id": "4f2ca20c-cffb-456b-aa0f-5255702a24ec"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Sorafenib-induced Prostate Volume Reduction, a New Adverse Effect Detected by Imaging: A Pilot Study", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Sorafenib-induced Prostate Volume Reduction, a New Adverse Effect Detected by Imaging: A Pilot Study", "subitem_title_language": "en"}]}, "item_type_id": "5", "owner": "1", "path": ["2189", "6648", "1285", "1778", "7804"], "permalink_uri": "http://hdl.handle.net/2241/00159307", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-01-16"}, "publish_date": "2020-01-16", "publish_status": "0", "recid": "53889", "relation": {}, "relation_version_is_last": true, "title": ["Sorafenib-induced Prostate Volume Reduction, a New Adverse Effect Detected by Imaging: A Pilot Study"], "weko_shared_id": 5}
Sorafenib-induced Prostate Volume Reduction, a New Adverse Effect Detected by Imaging: A Pilot Study
http://hdl.handle.net/2241/00159307
http://hdl.handle.net/2241/001593079844025f-21f7-4a9d-b35a-022af651b01c
名前 / ファイル | ライセンス | アクション |
---|---|---|
JBSR_102-1 (3.8 MB)
|
Item type | Journal Article(1) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
公開日 | 2020-01-16 | |||||||||||
タイトル | ||||||||||||
言語 | en | |||||||||||
タイトル | Sorafenib-induced Prostate Volume Reduction, a New Adverse Effect Detected by Imaging: A Pilot Study | |||||||||||
言語 | ||||||||||||
言語 | eng | |||||||||||
資源タイプ | ||||||||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||||||||
タイプ | journal article | |||||||||||
著者 |
森, 健作
× 森, 健作× 小島, 崇宏× 福田, 邦明× 高橋, 一広
WEKO
204474
× Takahashi, Hiroaki× Masuoka, Sota× Nasu, Katsuhiro× Ishiguro, Toshitaka× Hosokawa, Takahiro× Minami, Manabu |
|||||||||||
抄録 | ||||||||||||
内容記述タイプ | Abstract | |||||||||||
内容記述 | Background: Sorafenib has been used in the treatment of advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). Sorafenib-associated organ reduction have been reported on imaging, such as thyroid, pancreas and muscle, but there has been no research on prostate volume reduction (PVR). Methods: We retrospectively analyzed 26 patients (twenty with HCC and six patients with RCC) who underwent sorafenib therapy for 31 to 1225 days (median, 100 days). PVR was estimated by two independent readers using CT volumetry. Results: The sum of all prostate volumes measured by reader 1 was 24.2 ± 13.8 cm3 on the baseline CT and 20.4 ± 10.6 cm3 on the follow-up CT (p < 0.001), and that measured by reader 2 was 22.3 ± 13.9 cm3 on the baseline CT and 19.2 ± 10.6 cm3 on the follow-up CT (p < 0.001). The concordance correlation coefficient for the prostate volume measured by the two readers was 0.95 on the baseline CT scans and 0.94 on the follow-up CT scans. Sorafenib-associated PVR demonstrated slight dependence to the exposure time (r = –0.23). One patient with benign prostatic hyperplasia (BPH) showed PVR (from 80.4 to 61.5 cm3 [reader 1]; 83.4 to 61.6 cm3 [reader 2]) after sorafenib administration. Sorafenib-associated PVR occurred in patients both with and without underlying liver dysfunction with relative prostate volume changes of 86.7 ± 12.0% and 85.0 ± 9.0%, respectively. Conclusion: Our study demonstrated significant PVR with sorafenib treatment in patients regardless of the presence of BPH and underlying liver dysfunction. |
|||||||||||
書誌情報 |
en : Journal of the Belgian Society of Radiology 巻 102, 号 1, p. 69, 発行日 2018-10 |
|||||||||||
ISSN | ||||||||||||
収録物識別子タイプ | ISSN | |||||||||||
収録物識別子 | 2514-8281 | |||||||||||
PubMed番号 | ||||||||||||
識別子タイプ | PMID | |||||||||||
関連識別子 | 30386849 | |||||||||||
DOI | ||||||||||||
識別子タイプ | DOI | |||||||||||
関連識別子 | 10.5334/jbsr.1607 | |||||||||||
権利 | ||||||||||||
権利情報 | © 2018 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/. | |||||||||||
著者版フラグ | ||||||||||||
値 | publisher | |||||||||||
出版者 | ||||||||||||
出版者 | Ubiquity Press |